ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
A Genome-Wide Scan For Quantitative Trait Loci of Serum Bilirubin - A Framingham Study

This study is ongoing, but not recruiting participants.

Sponsored by: National Heart, Lung, and Blood Institute (NHLBI)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00340509
  Purpose

Studies have shown that there is a significant association between serum bilirubin concentrations and risk of coronary artery disease (CAD). So far, no linkage analysis in humans between serum bilirubin and DNA markers has been reported. The purpose of this protocol is to identify chromosome regions that contain quantitative trait loci (QTL) involved in serum bilirubin metabolism and bilirubin concentration. In the Framingham Study, a 10cM genome scan (about 400 markers) has been conducted in more than three hundred families. Serum bilirubin was measured in the first and second exams of the Framingham Offspring. These data provide us the opportunity to undertake linkage analyses to map QTL of serum bilirubin.


Condition
Genetics

MedlinePlus related topics:   Nuclear Scans   

U.S. FDA Resources

Study Type:   Observational
Official Title:   A Genome-Wide Scan For Quantitative Trait Loci of Serum Bilirubin - A Framingham Study

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment:   330
Study Start Date:   October 2001

Detailed Description:

Many studies showed that there is a significant relationship between serum bilirubin levels and risk of coronary artery disease (CAD). We carried out a genome-wide scan for quantitative trait loci of serum bilirubin through the 330 extended Framingham families and found significant evidence of linkage of serum bilirubin to chromosome 2q telomere where an important candidate gene, Uridine diphosphate glycosyltransferase 1 gene (UGT1A1), resides. The purposes of this protocol are to confirm linkage between serum bilirubin and UGT1A1, mathematical modeling and association studies between the genotypes of UGT1A1 and CAD.

  Eligibility
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria
  • INCLUSION CRITERIA:

The study population will include the members of the 330 Framingham Study families with genome scan.

The Original Cohort will also be included.

  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00340509

Locations
United States, Massachusetts
Boston University    
      Boston, Massachusetts, United States, 02118-2354

Sponsors and Collaborators
  More Information

Study ID Numbers:   999902016, 02-H-N016
First Received:   June 19, 2006
Last Updated:   July 18, 2008
ClinicalTrials.gov Identifier:   NCT00340509
Health Authority:   United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Genetics  
Population  
CHD Risk  
Epidemiology  
Gene Mapping  

Study placed in the following topic categories:
Bilirubin

ClinicalTrials.gov processed this record on September 05, 2008




Links to all studies - primarily for crawlers